ZA201205370B - Anaesthetic formulation - Google Patents

Anaesthetic formulation

Info

Publication number
ZA201205370B
ZA201205370B ZA2012/05370A ZA201205370A ZA201205370B ZA 201205370 B ZA201205370 B ZA 201205370B ZA 2012/05370 A ZA2012/05370 A ZA 2012/05370A ZA 201205370 A ZA201205370 A ZA 201205370A ZA 201205370 B ZA201205370 B ZA 201205370B
Authority
ZA
South Africa
Prior art keywords
anaesthetic formulation
anaesthetic
formulation
Prior art date
Application number
ZA2012/05370A
Other languages
English (en)
Inventor
Juliet Marguerite Goodchild
Colin Stanley Goodchild
Benjamin James Boyd
Original Assignee
Drawbridge Pharmaceuticals Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Drawbridge Pharmaceuticals Pty Ltd filed Critical Drawbridge Pharmaceuticals Pty Ltd
Publication of ZA201205370B publication Critical patent/ZA201205370B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Anesthesiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2012/05370A 2010-01-21 2012-07-18 Anaesthetic formulation ZA201205370B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29724910P 2010-01-21 2010-01-21
US38531810P 2010-09-22 2010-09-22
PCT/AU2011/000050 WO2011088503A1 (en) 2010-01-21 2011-01-19 Anaesthetic formulation

Publications (1)

Publication Number Publication Date
ZA201205370B true ZA201205370B (en) 2013-09-25

Family

ID=44306295

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2012/05370A ZA201205370B (en) 2010-01-21 2012-07-18 Anaesthetic formulation

Country Status (27)

Country Link
US (2) US8697678B2 (OSRAM)
EP (1) EP2525798B1 (OSRAM)
JP (1) JP5930311B2 (OSRAM)
KR (1) KR101747476B1 (OSRAM)
CN (1) CN102802635B (OSRAM)
AU (1) AU2011207103B2 (OSRAM)
BR (1) BR112012017800B1 (OSRAM)
CA (1) CA2786762C (OSRAM)
CL (1) CL2012002032A1 (OSRAM)
CY (1) CY1119947T1 (OSRAM)
DK (1) DK2525798T3 (OSRAM)
ES (1) ES2646829T3 (OSRAM)
GB (2) GB2491491B (OSRAM)
HR (1) HRP20171699T1 (OSRAM)
HU (1) HUE035441T2 (OSRAM)
LT (1) LT2525798T (OSRAM)
NO (1) NO2525798T3 (OSRAM)
NZ (1) NZ601255A (OSRAM)
PL (1) PL2525798T3 (OSRAM)
PT (1) PT2525798T (OSRAM)
RS (1) RS56576B1 (OSRAM)
RU (1) RU2574022C2 (OSRAM)
SG (1) SG181997A1 (OSRAM)
SI (1) SI2525798T1 (OSRAM)
SM (1) SMT201700518T1 (OSRAM)
WO (1) WO2011088503A1 (OSRAM)
ZA (1) ZA201205370B (OSRAM)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX336930B (es) 2005-11-28 2016-02-05 Marinus Pharmaceuticals Formulaciones de ganaxolona y metodos para la manufactura y el uso de las mismas.
WO2013043985A1 (en) 2011-09-23 2013-03-28 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
CA2852716C (en) * 2011-11-29 2015-11-17 Jurox Pty Ltd Methods of preserving injectable pharmaceutical compositions comprising a cyclodextrin and a hydrophobic drug
DK2806877T3 (da) * 2012-01-23 2019-11-04 Sage Therapeutics Inc Neuroaktive steroidformuleringer omfattende et kompleks af allopregnanolon og sulfobutylether beta-cyclodekstrin
US20140050789A1 (en) 2012-08-13 2014-02-20 The Regents Of The University Of California Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids
CA2882708A1 (en) * 2012-08-21 2014-02-27 Sage Therapeutics, Inc. Methods of treating epilepsy or status epilepticus
EP2916846B1 (en) * 2012-11-09 2025-09-17 Drawbridge Pharmaceuticals Pty Ltd Neuroactive steroids and their use to facilitate neuroprotection
JP2016501876A (ja) * 2012-11-30 2016-01-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ステロイドの抗痙攣活性
WO2015134670A1 (en) * 2014-03-05 2015-09-11 Mingbao Zhang Deuterated ganaxolone derivatives
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
CA3254865A1 (en) * 2015-02-06 2025-05-28 Marinus Pharmaceuticals, Inc. Intravenous ganaxolone formulations and their use in treating status epilepticus and other seizure disorders
MA45276A (fr) * 2015-06-18 2018-04-25 Sage Therapeutics Inc Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
MX2018004376A (es) * 2015-10-16 2018-08-01 Marinus Pharmaceuticals Inc Formulaciones inyectables de neuroesteroides que contienen nanoparticulas.
WO2017156103A1 (en) 2016-03-08 2017-09-14 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
KR102518846B1 (ko) 2016-08-11 2023-04-05 오비드 테라퓨틱스 인크. 간질 장애의 치료를 위한 방법 및 조성물
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
KR102356567B1 (ko) 2018-04-16 2022-02-08 카와사키 주코교 카부시키 카이샤 벨트 컨베이어
CN112384525A (zh) * 2018-07-03 2021-02-19 德劳布里奇制药有限公司 神经活性类固醇及制备方法
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
CA3123002A1 (en) * 2018-12-10 2020-06-18 Halo Science LLC Stable formulations of anesthetics and associated dosage forms
CA3145923A1 (en) 2019-08-05 2021-02-11 David Czekai Ganaxolone for use in treatment of status epilepticus
AU2020395254A1 (en) 2019-12-06 2022-06-02 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treating tuberous sclerosis complex
US11969434B1 (en) 2022-08-29 2024-04-30 Lipocine Inc. Oral allopregnanolone compositions and methods of use
US12186327B2 (en) 2022-08-29 2025-01-07 Lipocine Inc. Oral allopregnanolone compositions and methods of use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69006259T2 (de) * 1989-05-24 1994-06-09 Innovet Inc Hypoallergene anästhesierende/hypnotische steroide Arzneizubereitung.
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
WO1993017711A1 (en) * 1992-03-11 1993-09-16 Australian Commercial Research & Development Limited New cyclodextrins and new formulated drugs
US5472954A (en) * 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
JP4227675B2 (ja) * 1996-10-25 2009-02-18 康武 日地 神経毒軽減麻酔剤
AUPQ633900A0 (en) * 2000-03-20 2000-04-15 Jurox Pty Ltd Anaesthetic composition
RU2288921C2 (ru) * 2000-12-19 2006-12-10 Калифорниа Инститьют оф Текнолоджи Композиции, содержащие комплексы включения
US7034013B2 (en) 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
EP1383445A4 (en) * 2001-03-20 2005-04-13 Cydex Inc FORMULATIONS WITH PROPOFOL AND A SULFOALKYL ETHER CYCLODEXTRIN
IL152575A (en) * 2002-10-31 2008-12-29 Transpharma Medical Ltd A skin-to-skin transmission system of water-insoluble drugs
MX336930B (es) * 2005-11-28 2016-02-05 Marinus Pharmaceuticals Formulaciones de ganaxolona y metodos para la manufactura y el uso de las mismas.

Also Published As

Publication number Publication date
RS56576B1 (sr) 2018-02-28
CN102802635A (zh) 2012-11-28
PL2525798T3 (pl) 2018-05-30
US8975245B2 (en) 2015-03-10
SI2525798T1 (en) 2018-01-31
KR101747476B1 (ko) 2017-06-14
SMT201700518T1 (it) 2018-01-11
EP2525798B1 (en) 2017-08-09
HK1169031A1 (en) 2013-01-18
HRP20171699T1 (hr) 2018-01-26
EP2525798A1 (en) 2012-11-28
AU2011207103B2 (en) 2013-03-21
BR112012017800A2 (en) 2018-07-10
WO2011088503A1 (en) 2011-07-28
EP2525798A4 (en) 2014-02-19
NZ601255A (en) 2013-09-27
US8697678B2 (en) 2014-04-15
GB2491491A (en) 2012-12-05
CN102802635B (zh) 2014-07-30
US20140066417A1 (en) 2014-03-06
ES2646829T3 (es) 2017-12-18
RU2012134321A (ru) 2014-02-27
PT2525798T (pt) 2017-11-15
GB2491491B (en) 2014-07-30
CL2012002032A1 (es) 2012-12-21
CY1119947T1 (el) 2018-12-12
GB201210657D0 (en) 2012-08-01
GB2484244A (en) 2012-04-04
JP2013517299A (ja) 2013-05-16
HUE035441T2 (en) 2018-05-02
BR112012017800A8 (pt) 2018-08-14
US20120316146A1 (en) 2012-12-13
CA2786762A1 (en) 2011-07-28
JP5930311B2 (ja) 2016-06-08
CA2786762C (en) 2017-12-05
RU2574022C2 (ru) 2016-01-27
NO2525798T3 (OSRAM) 2018-01-06
AU2011207103A1 (en) 2012-07-26
KR20120136347A (ko) 2012-12-18
DK2525798T3 (da) 2017-11-20
GB2484244B (en) 2012-10-31
SG181997A1 (en) 2012-08-30
LT2525798T (lt) 2018-01-10
BR112012017800B1 (pt) 2020-12-08
GB201201842D0 (en) 2012-03-21

Similar Documents

Publication Publication Date Title
GB2484244B (en) Anaesthetic formulation
GB201010193D0 (en) Medicinal use
PL2552212T3 (pl) Ulepszona postać preparatu
ZA201206589B (en) Incotine containing formulation
SI2642980T1 (sl) Pediatrične formulacije
ZA201300194B (en) Formulations
GB201110193D0 (en) Formulations
GB201013513D0 (en) Formulations
GB201012721D0 (en) Headgear-mountable respirator
GB201011138D0 (en) Vaporiser
GB201006326D0 (en) Formulation
ZA201300196B (en) Formulations
HK1169031B (en) Anaesthetic formulation
GB201002000D0 (en) Formulation
GB201001978D0 (en) Formulation
GB201005992D0 (en) Formulation
PL393180A1 (pl) Preparat weterynaryjny
PL390421A1 (pl) Preparat weterynaryjny
GB201018649D0 (en) Formulations
GB201010494D0 (en) Formulations
GB201008470D0 (en) Formulations
GB201008358D0 (en) Formulations
GB201007959D0 (en) Formulations
GB201007702D0 (en) Formulations
GB201012589D0 (en) Formulations